Welcome to our dedicated page for LAVA Therapeutics N.V. Ordinary Shares news (Ticker: LVTX), a resource for investors and traders seeking the latest updates and insights on LAVA Therapeutics N.V. Ordinary Shares stock.
LAVA Therapeutics N.V. (Nasdaq: LVTX) is a pioneering biotechnology company that specializes in transforming cancer treatment through its innovative Gammabody® platform. This platform harnesses bispecific gamma-delta T cell engagers designed to target and eliminate cancer cells. The company focuses on both solid tumors and hematologic malignancies, aiming to deliver groundbreaking therapies for patients with unmet medical needs.
One of LAVA's lead programs is LAVA-1207, which targets the prostate-specific membrane antigen (PSMA) to treat metastatic castration-resistant prostate cancer (mCRPC). This program has shown a favorable safety profile and preliminary signs of anti-tumor activity in ongoing Phase 1/2a clinical trials across Europe and the United States. Recently, LAVA announced a collaboration with Merck & Co., Inc., Rahway, NJ, USA to evaluate LAVA-1207 in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
In addition to LAVA-1207, the company is advancing other promising candidates such as PF-08046052, formerly known as LAVA-1223, which targets EGFR-positive tumors and is being developed under a license agreement with Pfizer. LAVA is also preparing an IND submission for LAVA-1266, a treatment targeting CD123 for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Financially, LAVA is well-positioned, with a focus on extending its cash runway into 2026 through strategic prioritization of its pipeline. The company has formed valuable collaborations, including partnerships with Seagen and Pfizer, to advance its clinical programs and support its growth trajectory.
For more detailed information on LAVA Therapeutics, visit their official website at www.lavatherapeutics.com and follow them on LinkedIn, X (formerly Twitter), and YouTube.
LAVA Therapeutics (Nasdaq: LVTX) announced that the FDA granted orphan drug designation for LAVA-051, a bispecific antibody targeting chronic lymphocytic leukemia (CLL). The designation will facilitate communication with the FDA and provide incentives for development, such as tax credits and potential market exclusivity. LAVA-051 is currently in a Phase 1/2a clinical trial for relapsed or refractory CLL, multiple myeloma, and acute myeloid leukemia, with preliminary data expected in 2022.
LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, announced that Hans van der Vliet, M.D., Ph.D., their chief scientific officer, will present at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. The presentation will highlight their bispecific gamma delta T cell engagers, focusing on V9V2 T cells and preclinical data from the LAVA-051 program. The session is set for October 8, 2021, from 12:05 to 1:55 p.m. ET.
LAVA Therapeutics (Nasdaq: LVTX) reported progress in its clinical trials and financial results for Q2 2021. The Phase 1/2a trial of LAVA-051 for hematological malignancies has initiated dosing, with results expected in early 2022. The CTA and IND for LAVA-1207 in metastatic castration-resistant prostate cancer have been accepted, with enrollment beginning later this year. The company holds a cash balance of €128.4 million, expected to fund operations into late 2023. Revenue from its collaboration with Janssen increased, but net losses grew to €5.8 million for Q2.
LAVA Therapeutics N.V. (Nasdaq: LVTX) has appointed Amy Garabedian as its new general counsel and corporate secretary. With over 15 years of experience in the life sciences sector, Garabedian previously served as associate general counsel at Spark Therapeutics. Her expertise in corporate and strategic legal matters is expected to bolster LAVA's clinical development efforts as it advances its bispecific gamma-delta T cell engagers for cancer treatment. LAVA plans to report Phase 1 clinical data in 2022, reinforcing its commitment to innovative cancer therapies.
LAVA Therapeutics (Nasdaq: LVTX) has initiated the dosing of the first patient in its Phase 1/2a clinical trial for LAVA-051, aimed at treating relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and acute myeloid leukemia (AML). This bispecific gamma-delta T cell engager (bsTCE) selectively targets CD1d-expressing cancers, potentially overcoming limitations of previous treatments. The trial, initially conducted in Europe, is a critical step towards enhancing treatment options for patients with these challenging hematological malignancies.
LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that CEO Stephen Hurly will present at the 2021 Jefferies Virtual Healthcare Conference on June 1, 2021, at 11:30 a.m. ET. The presentation will be available via webcast on the company's website. LAVA is a biotechnology firm focusing on bispecific gamma-delta T cell engagers aimed at treating solid tumors and hematological malignancies. The company plans to release clinical data for LAVA-051 by mid-2022 and initiate a clinical study for LAVA-1207 in prostate cancer in late 2021.
LAVA Therapeutics reported a significant cash position of $160 million following its IPO, expected to fund operations through at least the second half of 2023.
The company is on track to initiate a Phase 1/2a trial for LAVA-051 targeting hematological malignancies. Preclinical data showed promising anti-tumor activity at the AACR Virtual 2021 Meeting.
First-quarter results revealed a net loss of €16.6 million and increased operational expenses, attributed mainly to an uptick in research and development costs. Total cash and equivalents rose from €12.9 million in Q4 2020 to €134.7 million by March 31, 2021.
LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that CEO Stephen Hurly will present at the 2021 UBS Global Healthcare Virtual Conference on May 26 at 1:00 p.m. ET. Attendees can access the presentation via the investor relations section of the company’s website. LAVA focuses on developing bispecific gamma-delta T cell engagers aimed at treating solid tumors and hematological malignancies. A Phase 1/2a clinical study for LAVA-051 is expected to yield data in early 2022, and a study for LAVA-1207 in prostate cancer is scheduled for the second half of 2021.
LAVA Therapeutics N.V. (Nasdaq: LVTX) has appointed Karen J. Wilson to its Board of Directors and as chair of the Audit Committee. With over 30 years of experience in finance within the life sciences sector, Wilson's leadership is expected to enhance LAVA's strategic direction. The company anticipates two clinical candidates will enter trials in 2021 following a successful IPO. CEO Stephen Hurly emphasized her expertise in both clinical and commercial stages, which is crucial as LAVA advances its bispecific gamma-delta T cell engager platform aimed at improving cancer treatment.
FAQ
What is the current stock price of LAVA Therapeutics N.V. Ordinary Shares (LVTX)?
What is the market cap of LAVA Therapeutics N.V. Ordinary Shares (LVTX)?
What is LAVA Therapeutics N.V.?
What is the Gammabody® platform?
What is LAVA-1207?
What recent achievements has LAVA Therapeutics made?
Who are LAVA Therapeutics' key partners?
Where are LAVA Therapeutics' clinical trials conducted?
What is PF-08046052?
What is the financial outlook for LAVA Therapeutics?
How does LAVA-1207 work?
Where can I find more information about LAVA Therapeutics?
